See the DrugPatentWatch profile for olaparib

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has shown significant promise in the treatment of various types of cancer, particularly ovarian and breast cancers with defects in homologous recombination repair (HRR) [1]. It was first approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of advanced ovarian cancer [1].

The patent for olaparib, held by AstraZeneca, is set to expire in 2023 in the United States [2]. This means that, after this date, other pharmaceutical companies will be able to produce and sell generic versions of the drug, potentially increasing accessibility and reducing costs [2].

However, it is important to note that the availability of olaparib may also depend on other factors, such as regulatory approvals for new indications, pricing decisions by manufacturers, and reimbursement policies by healthcare payers [1].

In summary, while the patent for olaparib is set to expire in 2023, its widespread availability may depend on various factors beyond the patent expiration date.

Sources:

1. "Olaparib." National Comprehensive Cancer Network, www.nccn.org/professionals/physician_gls/pdf/olaparib.pdf.
2. "Olaparib (Lynparza)." DrugPatentWatch, 28 Jan. 2021, www.drugpatentwatch.com/drugs/olaparib.
3. "Olaparib." MedlinePlus, U.S. National Library of Medicine, medlineplus.gov/druginfo/meds/a616042.html.